CN101204372A - 马来酸桂哌齐特注射液及其制备方法 - Google Patents
马来酸桂哌齐特注射液及其制备方法 Download PDFInfo
- Publication number
- CN101204372A CN101204372A CNA2007101156089A CN200710115608A CN101204372A CN 101204372 A CN101204372 A CN 101204372A CN A2007101156089 A CNA2007101156089 A CN A2007101156089A CN 200710115608 A CN200710115608 A CN 200710115608A CN 101204372 A CN101204372 A CN 101204372A
- Authority
- CN
- China
- Prior art keywords
- cinepazide maleate
- injection
- cinepazide
- preparation
- disodium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XSTJTOKYCAJVMJ-GVTSEVKNSA-N (z)-but-2-enedioic acid;(e)-1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound OC(=O)\C=C/C(O)=O.COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 XSTJTOKYCAJVMJ-GVTSEVKNSA-N 0.000 title claims abstract description 120
- 229960004201 cinepazide Drugs 0.000 title claims abstract description 120
- 238000002347 injection Methods 0.000 title claims abstract description 52
- 239000007924 injection Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 63
- 239000000243 solution Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008215 water for injection Substances 0.000 claims abstract description 11
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 61
- 235000019800 disodium phosphate Nutrition 0.000 claims description 61
- 239000001488 sodium phosphate Substances 0.000 claims description 34
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 27
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 27
- 229960002920 sorbitol Drugs 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 7
- 238000005304 joining Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 8
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000012535 impurity Substances 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 238000011835 investigation Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
考察时间 | 有关物质 | 马来酸桂哌齐特顺式异构体含量% | ||
200500801(pH:4.01) | 200500802(pH:3.95) | 200500803(pH:3.90) | ||
0天10天 | 顺式异构体其他杂质顺式异构体其他杂质 | 0.3120.2980.3850.301 | 0.3610.3000.4700.305 | 0.2640.3030.3910.299 |
考察时间 | 有关物质 | 马来酸桂哌齐特顺式异构体含量% | ||||||||||
3.5 | 3.6 | 3.7 | 3.8 | 3.9 | 4.0 | 4.1 | 4.2 | 4.3 | 4.4 | 4.5 | ||
0天10天 | 顺杂顺杂 | 0.2270.2790.8200.275 | 0.2330.2680.7950.272 | 0.2320.2720.6270.284 | 0.2290.2760.5060.269 | 0.2340.2650.4210.270 | 0.2350.2640.3800.271 | 0.2240.2570.3300.258 | 0.2300.2840.3330.279 | 0.2250.2870.3820.281 | 0.2230.2660.4110.267 | 0.2310.2770.5870.280 |
考察时间 | 有关物质 | 马来酸桂哌齐特顺式异构体含量% | |
1M氢氧化钠作为pH调节剂的溶液 | 10%磷酸氢二钠氢氧化钠作为pH调节剂的溶液 | ||
0天30天 | 顺式异构体其他杂质顺式异构体其他杂质 | 0.2300.2720.4960.274 | 0.1210.2800.1290.277 |
考察时间 | 有关物质 | 马来酸桂哌齐特顺式异构体含量% | |||
5% | 10% | 15% | 20% | ||
0天30天 | 顺式异构体其他杂质顺式异构体其他杂质 | 0.1460.2930.1550.289 | 0.1420.2690.1470.271 | 0.1500.2720.1600.274 | 0.1490.2730.1510.279 |
考察时间 | 有关物质 | 马来酸桂哌齐特顺式异构体含量% | |||||
工艺1 | 工艺2 | 工艺3 | 工艺4 | 工艺5 | 工艺6 | ||
0天30天 | 顺式异构体其他杂质顺式异构体其他杂质 | 0.2550.2830.2700.295 | 0.2580.2900.2620.293 | 0.2060.2310.2220.243 | 0.1580.2730.1760.279 | 0.1190.2740.1240.275 | 0.2370.2680.2520.271 |
考察时间 | 有关物质 | 马来酸桂哌齐特顺式异构体含量% | |||||
样品1 | 样品2 | 样品3 | 样品4 | 样品5 | 样品6 | ||
0天30天 | 顺式异构其他杂质顺式异构其他杂质 | 0.2430.2880.2500.294 | 0.2090.2760.2170.271 | 0.1660.2910.1730.283 | 0.1570.2790.1640.280 | 0.1560.2750.1690.286 | 0.1610.2810.1700.285 |
考察时间 | 本发明马来酸桂哌齐特注射液 | 上市马来酸桂哌齐特注射液 | ||||
含量 | 顺式异构体 | 其他杂质 | 含量 | 顺式异构体 | 其他杂质 | |
0天30天 | 98.3298.41 | 0.1610.165 | 0.2980.301 | 99.2799.15 | 0.2490.416 | 0.3200.325 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101156089A CN101204372B (zh) | 2007-12-17 | 2007-12-17 | 马来酸桂哌齐特注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101156089A CN101204372B (zh) | 2007-12-17 | 2007-12-17 | 马来酸桂哌齐特注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101204372A true CN101204372A (zh) | 2008-06-25 |
CN101204372B CN101204372B (zh) | 2011-10-19 |
Family
ID=39565002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101156089A Active CN101204372B (zh) | 2007-12-17 | 2007-12-17 | 马来酸桂哌齐特注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101204372B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101518513B (zh) * | 2009-04-08 | 2010-10-27 | 邓菊娟 | 一种马来酸桂哌齐特脂微球制剂及其制备方法 |
CN101708179B (zh) * | 2009-08-17 | 2011-06-01 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN102100695B (zh) * | 2009-08-17 | 2012-01-11 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN102688188A (zh) * | 2012-06-13 | 2012-09-26 | 江苏神龙药业有限公司 | 马来酸桂哌齐特注射液及其制备方法 |
CN105832662A (zh) * | 2016-05-12 | 2016-08-10 | 河北仁合益康药业有限公司 | 一种马来酸桂哌齐特注射液组合物及其制备方法 |
CN108309929A (zh) * | 2017-01-15 | 2018-07-24 | 湖南格制药有限公司 | 一种马来酸桂哌齐特注射液及其制备方法 |
-
2007
- 2007-12-17 CN CN2007101156089A patent/CN101204372B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101518513B (zh) * | 2009-04-08 | 2010-10-27 | 邓菊娟 | 一种马来酸桂哌齐特脂微球制剂及其制备方法 |
CN101708179B (zh) * | 2009-08-17 | 2011-06-01 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN102100695B (zh) * | 2009-08-17 | 2012-01-11 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN102688188A (zh) * | 2012-06-13 | 2012-09-26 | 江苏神龙药业有限公司 | 马来酸桂哌齐特注射液及其制备方法 |
CN102688188B (zh) * | 2012-06-13 | 2016-06-22 | 江苏神龙药业有限公司 | 马来酸桂哌齐特注射液及其制备方法 |
CN105832662A (zh) * | 2016-05-12 | 2016-08-10 | 河北仁合益康药业有限公司 | 一种马来酸桂哌齐特注射液组合物及其制备方法 |
CN108309929A (zh) * | 2017-01-15 | 2018-07-24 | 湖南格制药有限公司 | 一种马来酸桂哌齐特注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101204372B (zh) | 2011-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101204372B (zh) | 马来酸桂哌齐特注射液及其制备方法 | |
CN103768091B (zh) | 碳酸氢钠注射液及其制备方法 | |
CN101068544B (zh) | 在将它们施用于身体时具有改善的稳定凝胶化的放射性核素-脱乙酰壳多糖复合物和它们的制备方法 | |
CN101007003A (zh) | 一种稳定的托拉塞米注射液及其制备方法 | |
CN101569603B (zh) | 一种含有多索茶碱的水针剂及其制备方法 | |
Akkerman et al. | Stability of milrinone lactate in the presence of 29 critical care drugs and 4 iv solutions | |
CN108066339B (zh) | 一种帕瑞昔布钠的药物组合物 | |
CN105125484A (zh) | 一种无痛化的多西环素注射液及其制备方法 | |
CN102688185B (zh) | 一种稳定的帕洛诺司琼注射液及其制备方法 | |
CN101507747B (zh) | 黄芪总皂苷氯化钠注射液的制备方法 | |
CN103083338B (zh) | 增效复方安乃近注射液及其制备方法 | |
CN103202805B (zh) | 一种含有长春西汀的注射用药物组合物及其制备方法 | |
CN101474147B (zh) | 一种马来酸桂哌齐特注射液及其制备方法 | |
CN102688188B (zh) | 马来酸桂哌齐特注射液及其制备方法 | |
CN105982852A (zh) | 一种盐酸多巴胺注射液及其制备方法 | |
CN101601647B (zh) | 一种核黄素磷酸钠组合物注射液及制备方法 | |
CN104906039A (zh) | 一种替米考星注射用混悬剂及其制备方法 | |
Bianchi et al. | Stability and compatibility of drug mixtures in an implantable infusion system | |
CN100356170C (zh) | 一种治疗癌性疼痛中药组合物的质量控制方法及应用 | |
CN1830434A (zh) | 一种曲克芦丁注射液的制备方法 | |
CN104490903B (zh) | 一种复方维生素注射液药物组合物及其制备方法 | |
CN103211827B (zh) | 一种复方阿莫西林油混悬液组方及其制备方法 | |
CN101152171B (zh) | 一种米屈肼注射液的制备方法 | |
CN104666334A (zh) | 葡萄糖氯化钠钾注射液组合物 | |
CN102949413B (zh) | 一种转化糖电解质注射液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN SIHUAN PHARMACEUTICAL CO., LTD.; APPLICANT Free format text: FORMER OWNER: CHE FENGSHENG Effective date: 20081010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Che Fengsheng Document name: Notification of the application for patent for invention to go through the substantive examination procedure |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20081010 Address after: Room 6304, office building, Jinhua sea logistics center, 14A, Hainan, Hainan Yangpu Economic Development Zone, zip code: 570125 Applicant after: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Co-applicant after: Beijing Sihuan Pharmaceutical Co., Ltd. Co-applicant after: Hainan Sihuan Research Institute of Cardio-cerebral Vascular Medicine Co., Ltd. Address before: The new business building, No. 48 Hainan Province, Haikou city China World Trade Center road 31 layer post encoding: 250101 Applicant before: Che Fengsheng |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Sun Changlong Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Che Fengsheng Inventor after: Huang Xiaoxia Inventor before: Che Fengsheng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHE FENGSHENG TO: CHE FENGSHENG HUANG XIAOXIA |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210715 Address after: 101114 Beijing city Tongzhou District Zhangjiawan Village East Shanzhuang Qi Patentee after: BEIJING SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee after: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Address before: 570125, Hainan Yangpu Economic Development Zone 14A Hainan Jinhua sea logistics center office building, room 6304 Patentee before: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee before: BEIJING SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee before: Hainan Sihuan Cardiovascular Drug Research Institute Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 570125 room 6304, office building of Hainan jinhuahai logistics center, 14a, Yangpu Economic Development Zone, Danzhou City, Hainan Province Patentee after: Hainan Sihuan Pharmaceutical Co., Ltd Patentee after: Beijing Sihuan Pharmaceutical Co., Ltd Address before: 101114 east of qishanzhuang village, Zhangjiawan, Tongzhou District, Beijing Patentee before: Beijing Sihuan Pharmaceutical Co., Ltd Patentee before: Hainan Sihuan Pharmaceutical Co., Ltd |